Tedizolid Phosphate API Manufacturers
compare suppliers & get competitive offers
Filters
Reset
Selected filters:
Type
Production region
Qualifications
Country of origin
Follow us
Distributor
Produced in:
Established in: 2005
MOQ: -
Employees: 200+
Portfolio of over 2,000 APIs
Precise quality control
End-to-end global regulatory support
+ 0
All certificates
Replies quickly
How does it work?
You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry
Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only
Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week
Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news
Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module
Looking for Tedizolid Phosphate API 856867-55-5?
- Description:
- Here you will find a list of producers, manufacturers and traders of Tedizolid Phosphate. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Tedizolid Phosphate
- Synonyms:
- Tedizolid , Torezolid Phosphate
- Cas Number:
- 856867-55-5
- DrugBank number:
- DB09042
- Unique Ingredient Identifier:
- O7DRJ6R4DW
About Tedizolid Phosphate
Why are people looking for Tedizolid phosphate? Drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and penicillin-resistant Streptococcus penumoniae, represent a massive public health threat Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved linezolid and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than linezolid Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®). This product is currently available as both an oral tablet and as a powder for intravenous injection.
You can ask the supplier for more technical information about the product.
Tedizolid Phosphate is a type of Oxazolidinonen
Oxazolidinones are a prominent subcategory of pharmaceutical Active Pharmaceutical Ingredients (APIs) that play a crucial role in the development of various medicinal compounds. These compounds are characterized by a five-membered heterocyclic ring, containing both oxygen and nitrogen atoms, which confers unique chemical properties and pharmacological activities.
Oxazolidinones have garnered significant attention in the pharmaceutical industry due to their potent antibacterial properties, particularly against multidrug-resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Their mechanism of action involves inhibiting bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome, thereby preventing the formation of functional protein complexes.
In addition to their antibacterial activity, oxazolidinones exhibit favorable pharmacokinetic properties, including good oral bioavailability, broad tissue distribution, and a low incidence of drug-drug interactions. These characteristics make them highly desirable for the treatment of severe bacterial infections, including pneumonia, skin and soft tissue infections, and complicated intra-abdominal infections.
Furthermore, the development of novel oxazolidinones and their derivatives has led to the discovery of compounds with improved efficacy and reduced toxicity. Pharmaceutical companies are actively engaged in research and development efforts to optimize the chemical structure of oxazolidinones, aiming to enhance their antibacterial activity spectrum and overcome emerging resistance mechanisms.
In conclusion, oxazolidinones represent a crucial subcategory of pharmaceutical APIs with potent antibacterial properties and favorable pharmacokinetic profiles. Ongoing research in this field holds great promise for the development of innovative drugs to combat challenging bacterial infections and improve patient outcomes.
Tedizolid Phosphate (Oxazolidinonen), classified under Anti-infective Agents
Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.
Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.
The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.
The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.
In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.
Tedizolid Phosphate manufacturers | traders | suppliers
We have 1 companies offering Tedizolid Phosphate produced in 1 different countries.
Get in contact with the supplier of your choice:
- LGM Pharma from United States, product country of origin World
Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.
You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.
